Human papillomavirus E7 protein induces homologous recombination defects and PARPi sensitivity

Siqi He,Ao Wang,Jing Wang,Zizhi Tang,Xiaojun Wang,Danqing Wang,Jie Chen,Cong Liu,Mingcai Zhao,Hui Chen,Liang Song
DOI: https://doi.org/10.1007/s00432-023-05511-6
2024-01-25
Journal of Cancer Research and Clinical Oncology
Abstract:Cervical cancer is a common gynecological malignancy, pathologically associated with persistent infection of high-risk types of human papillomavirus (HPV). Previous studies revealed that HPV-positive cervical cancer displays genomic instability; however, the underlying mechanism is not fully understood.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore how high - risk human papillomavirus (HPV) E7 protein affects the DNA damage repair mechanism, especially homologous recombination repair (HR), and to study whether this effect makes cervical cancer cells sensitive to poly ADP - ribose polymerase inhibitors (PARPi). Specifically, the paper aims to answer the following key questions: 1. **The influence of HPV E7 protein on DNA damage repair**: - Does the HPV E7 protein interfere with the DNA double - strand break (DSB) repair mechanism? - How does the E7 protein affect the efficiency of homologous recombination repair (HR)? 2. **The relationship between homologous recombination deficiency (HRD) induced by HPV E7 protein and PARPi sensitivity**: - Do cells expressing the E7 protein show increased sensitivity to PARPi? - Can this sensitivity be explained by the synthetic lethal effect? 3. **Potential treatment strategies**: - Can HPV E7 - induced HRD be a new target for cervical cancer treatment? - Can the use of PARPi provide a new treatment approach for HPV - positive cervical cancer patients? Through these studies, the authors hope to reveal the mechanism of action of HPV E7 protein in the occurrence and development of cervical cancer and provide a theoretical basis for the development of new treatment methods for HPV - positive cervical cancer. ### Overview of research methods To answer the above questions, the researchers adopted the following experimental methods: - **Tissue sample analysis**: By performing immunofluorescence staining on cervical intraepithelial neoplasia (CIN) and cervical cancer tissues at different stages, changes in DNA damage markers (such as γH2AX, pATM, 53BP1, etc.) were evaluated. - **Cell experiments**: HA - tagged HPV16 E6 and E7 genes were transfected into HEK293T and C33A cells respectively, and the effects on the phosphorylation levels of DNA damage response (DDR) - related proteins were detected. - **Homologous recombination repair ability assessment**: The formation of RPA32 - pS33 and RAD51 foci was detected by immunofluorescence staining to evaluate the effect of E7 expression on DSB repair ability. - **PARPi sensitivity test**: The survival rate changes of E7 - expressing cells under PARPi (such as olaparib) treatment were determined by colony - forming assay and CCK8 method. ### Main conclusions Studies have shown that the HPV E7 protein does interfere with the DNA double - strand break repair process, leading to homologous recombination repair deficiency (HRD). This deficiency makes E7 - expressing cells more sensitive to PARPi, indicating that HPV E7 - induced HRD may become a new target for cervical cancer treatment. In addition, E7 - induced HRD cannot be completely reversed by E6 - mediated p53 degradation, suggesting that the effect of E7 on HRD is independent. ### Formula representation Some key molecular mechanisms involved in the paper can be represented by formulas as follows: - **DNA double - strand break repair**: \[ DSB \xrightarrow{\text{HR}} ssDNA \xrightarrow{\text{RAD51}} Homologous\ Recombination \] Among them, the E7 protein interferes with the generation of ssDNA, thereby affecting RAD51 - mediated homologous recombination repair. - **PARPi sensitivity**: \[ HRD + PARPi \rightarrow Increased\ Chromosomal\ Aberrations \rightarrow Cell\ Death \] These formulas help to understand how the E7 protein makes cells sensitive to PARPi by interfering with HRD.